Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Study Says Some Long-Term Drug Use Harmful To Elderly

This article was originally published in PharmAsia News

Executive Summary

An Australian study concluded many drugs commonly used by the elderly are useless in the long term and may even retard improvement in some conditions. The study by the University of Sydney pointed to drugs that affect the brain and nervous system as particular instances where improvement actually results from behind taken off drugs after a while. It said patients taken off sleeping pills and antidepressants after a while saw improvement in their mental abilities and were less likely to fall down. Blood-pressure drugs also were unnecessary for 85 percent of patients aged 65 and older as long as six months to five years after being taken off the drugs and that sector recorded no increase in death rate, the study said. The lead researcher said many drugs have not been studied sufficiently in elderly people. (Click here for more

You may also be interested in...

Vous Has Advisors To Guide Growth In Promising Personalized Vitamin Space

Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.

Targeting Exciting Inflammasome Field, NodThera Raises $55m

UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.

Mylan And Pfizer Announce Key Date For Viatris Merger

Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts